Dentis’ Largest Shareholder Pledges 20% of Shares as Collateral, Adding to Overhang Risk From CBs

Dentis CEO and largest shareholder Shim Gi-bong pledged 1,826,000 Dentis shares as collateral to Korea Securities Finance and borrowed 2.46192 billion won. The contract runs from Aug. 28, 2025, to Feb. 28, 2027, with an interest rate of 5.04% and a collateral maintenance ratio of 110%.

The disclosure revealed the full volume of Shim’s share-pledge agreements. In addition to the Korea Securities Finance contract, the pledges include 770,000 shares to iM Bank, 317,248 shares to Hana Securities and 247,219 shares to Hanyang Securities, bringing the total pledged to 3,160,467 shares. That represents 19.99% of Dentis’ total shares outstanding, effectively placing one-fifth of its shares under collateral agreements.

Total collateral-backed loans exceed first-half operating profit

Shim’s total share-backed loans from multiple financial institutions amount to about 6.3 billion won. Dentis reported operating profit of about 5.7 billion won in the first half of 2026, meaning the largest shareholder’s personal collateral-backed loans exceed the company’s operating profit for the entire half-year. Shim and 14 related parties hold 4,539,434 Dentis shares, or 28.71%, while Shim personally holds 4,345,711 shares, or 27.48%.

The collateral maintenance ratio of 110% also warrants attention. If the share price falls below a certain level, financial institutions could immediately trigger a forced sale of the pledged shares, known as a margin call. Attorney Choi Jong-su of Sedam Law Firm said, "Whether the collateral holder forcibly sells the shares to recover the loan or takes ownership of the stake and becomes involved in management, either course could destabilize the business environment and negatively affect both the share price and management control."

Convertible bonds add to overhang pressure

The share pledges are compounded by risks from convertible bonds (CBs). Dentis issued new convertible bonds worth 8 billion won in August 2026 to repay existing debt. Following a decline in the share price, the conversion price was lowered from 8,452 won to 3,102 won, increasing the number of new shares that could enter the market to about 2.58 million. Combined, the largest shareholder’s pledged shares (3,160,467) and the shares awaiting conversion from CBs (about 2.58 million) amount to potential selling pressure well above one-third of shares outstanding.

FDA approvals arrive in succession as business growth takes hold

Separate from its financial risk factors, Dentis’ business is on a growth trajectory. Overseas sales accounted for 74.9% of revenue in the first half of 2026, while sales in the U.S. market rose 127.4% from the same period a year earlier. In September 2026, the company’s flagship dental unit chair, Lubis Chair, and its clear aligner material, MESHEET, received U.S. FDA approvals in succession. Founded in 2005, Dentis is a Korean medical device company that exports dental implants, surgical lights, clear aligners and other products to more than 67 countries.

Industry observers expect the resolution of Dentis’ financial risks to ultimately depend on its North American export performance. If its third plant, a new implant factory scheduled to begin operations at year-end, handles export volumes to North America and Europe and boosts cash generation, the company may be able to ease its current financial burden on its own. But market observers say that if the share price cannot be supported, forced sales and CB conversions could occur simultaneously, leading to risks to management control.